Conversely, MRPL genes with consistently established associations between expression and metastasis-related traits across a variety of cancer types (e.g. MRPL4, MRPL35 and MRPL42), are putative prognostic and therapeutic targets as they would have broad applicability across the cancer spectrum, thus directly benefit more patients. This evidence concerns the gene MRPL42 and cancer.